A phase II study of spirogermanium in advanced large bowel cancer. An Eastern Cooperative Oncology Group study.
Thirty-one patients with advanced colorectal cancer were entered on a phase II study of spirogermanium. Of these, 23 received the drug at the dose of 200 mg/m2 intravenously (i.v.) over 4 h twice a week every week. There were 2 (9%) partial responses. No complete responses were noted. Two life-threatening and six severe toxicities were observed. We conclude that this drug has some activity against colorectal cancer.
Pandya
K J
KJ
University of Rochester Cancer Center, New York.
Kramar
A
A
Asbury
R F
RF
Haller
D G
DG
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009942:Organometallic Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D013141:Spiro Compounds / Q000009:adverse effects / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D009942:Organometallic Compounds; D013141:Spiro Compounds; C026818:spirogermanium